Vestibular Versus Sublingual Route of AIT Tablets

Inclusion Criteria: * Written informed consent obtained before any trial related procedures are performed * Male or female of any race/ethnicity aged 18-65 years at the time of signing the informed consent * A clinically relevant history of birch pollen-, grass pollen-, ragweed pollen-, or HDM allergen-induced AR/C with or without asthma requiring treatment during the respective allergen season for birch pollen, grass pollen, or ragweed pollen, or perennial AR/C for HDM. * Positive SPT (5 mm wheal size or greater) to birch pollen, timothy grass pollen, ragweed pollen, or Dermatophagoides pteronyssinus/farinae within the previous 12 months * A device with daily access to the internet Exclusion Criteria: * • Previous SLIT-tablet treatment * Subcutaneous AIT treatment for the sensitized allergen within less than 5 years of screening * Severe acute or chronic oral inflammation. Subjects with acute oral inflammation may be randomised when the condition has been resolved * A history or diagnosis of eosinophilic oesophagitis * A relevant history of systemic allergic reaction e.g. anaphylaxis with cardiorespiratory symptoms, generalised urticaria or severe facial angioedema that in the opinion of the investigator may constitute an increased safety concern * Unstable, severe asthma (FEV1 \<70% of predicted value after adequate pharmacologic treatment) at randomisation * Currently taking beta-blockers